Key result
Adjunctive exenatide significantly reduced infarct size on CMR at 1 month compared with placebo in STEMI patients undergoing primary PCI (12.8±11.7 vs 26.4±11.6 g; P<0.01).
Why the study?
Does exenatide reduce infarct size in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention?
Population
58 patients with ST-segment-elevation myocardial infarction and thrombolysis in myocardial infarction flow 0…
Comparison
Exenatide administered subcutaneously at the… vs Placebo (saline) administered subcutaneously.
Design
RCT, Randomly assigned
Follow-up
6 months
Authors
Loading...
Adjunctive exenatide during primary PCI may limit injury in STEMI; extends GLP-1 agonist data to acute reperfusion.
RCT (n=58)
Randomly assigned
Does exenatide reduce infarct size in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention?
Absolute Event Rate: 12.8% vs 26.4%
p-value: p=<0.01
Adjunctive subcutaneous exenatide administered at the time of primary PCI significantly reduces infarct size and improves subclinical left ventricular function in patients with STEMI.
Woo et al. (2013) conducted an RCT in ST-segment-elevation myocardial infarction (n=58). Exenatide vs. Placebo (saline) was evaluated on Absolute mass of delayed hyperenhancement on cardiac magnetic resonance at 1 month (p=<0.01). Adjunctive exenatide significantly reduced infarct size on CMR at 1 month compared with placebo in STEMI patients undergoing primary PCI (12.8±11.7 vs 26.4±11.6 g; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: